Last updated: April 7, 2026
Up to 70% of cancer patients use some form of complementary therapy, yet research consistently shows that the majority never mention it to their oncologist. This silence is not a personal failing – it is a systemic communication gap with real consequences for patient safety and treatment outcomes. Understanding why this gap exists, what the latest science says, and how to bridge it can make a measurable difference in cancer care.
How Common Is Complementary Therapy Use Among Cancer Patients?
Complementary therapy use among cancer patients is widespread, with prevalence rates ranging from 33% to over 70% depending on the study and methodology. A 2019 JAMA Oncology study of 3,118 cancer patients found that 33.3% had used complementary and alternative medicine in the past year, while a 2023 Cancer Therapy Advisor survey reported that 70% of cancer patients used complementary or alternative medicine as part of their care.
The variation in these numbers reflects differences in how surveys define complementary therapies and where they are conducted. A 2026 review published through PMC noted that global CAM prevalence among cancer patients ranges from below 10% to over 90% depending on country and methodology. Regardless of which end of the spectrum a study captures, the conclusion is the same: complementary therapy use is the norm, not the exception.
Patients turn to these approaches for a variety of reasons – managing treatment side effects, supporting emotional wellbeing, regaining a sense of control, and improving quality of life. What makes this so significant for cancer care is that this widespread behavior exists largely in the shadows of the patient-oncologist relationship.
What Types of Complementary Therapies Do Cancer Patients Use Most Often?
The most commonly used complementary therapies among cancer patients span three broad categories: supplements, mind-body practices, and hands-on therapies.
| Category | Common Modalities | Notable Data Points |
|---|---|---|
| Supplements | Vitamin D, fish oil, herbal supplements | Vitamin D used by 32.1%, fish oil by 11.6% (Cancer Therapy Advisor, 2023) |
| Mind-Body Practices | Mindfulness, meditation, yoga | Highest nondisclosure rate among all categories (58.2% for mantra/mindfulness/spiritual meditation) |
| Hands-On Therapies | Acupuncture, massage | Both shown to reduce pain scores by 2.5-3 points in advanced cancer patients (JAMA Network Open, 2023) |
Supplements remain the most commonly used category overall, with vitamin D and fish oil leading the list. Mind-body practices such as meditation and yoga are increasingly popular but are also the least likely to be disclosed to a physician. Acupuncture and massage have gained significant clinical validation in recent years, particularly through trials at major cancer centers.
Is There a Difference Between Complementary and Alternative Cancer Therapies?
The distinction matters enormously for patient safety. According to the National Center for Complementary and Integrative Health (NCCIH), complementary therapies are used together with conventional cancer treatment, while alternative therapies are used in place of it. A complementary approach might involve acupuncture for chemotherapy-induced nausea alongside standard oncology protocols. An alternative approach would mean replacing chemotherapy with an unproven regimen entirely.
This distinction carries urgent weight given that a 2023 study published in The Oncologist found that 39% of U.S. adults believe cancer can be cured by alternative practices alone. Imprecise language – using “alternative” when “complementary” is meant – can reinforce dangerous misconceptions and lead patients away from effective treatment.
Why Don’t Cancer Patients Tell Their Oncologists About Complementary Therapies?
Cancer patients withhold information about complementary therapy use at rates ranging from 20% to 77% across published studies, driven primarily by three systemic factors: oncologists not asking, patients fearing disapproval, and patients believing disclosure is irrelevant. The most recent PMC review (2026) found that 61.1% of cancer patients reported never discussing complementary and alternative medicine with their physicians.
These numbers describe a communication failure, not patient dishonesty. A landmark 2009 qualitative study captured the dynamic in its title: “They Don’t Ask Me So I Don’t Tell Them.” The research found that patients consistently framed nondisclosure as a response to the structure of their medical encounters rather than an intentional decision to conceal information.
What Happens When Oncologists Simply Don’t Ask?
The single most common reason for nondisclosure is that physicians never initiate the conversation. The JAMA Oncology 2019 study found that 57.4% of patients who did not disclose complementary therapy use said their physician simply never asked. This placed the entire burden of disclosure on patients during appointments already dominated by scan results, treatment plans, and symptom management.
Nondisclosure patterns varied significantly by therapy type. Mantra, mindfulness, and spiritual meditation had the highest nondisclosure rate at 58.2%, while herbal supplements had the lowest at 11.8%. This suggests patients are more inclined to volunteer information about physical products they ingest than about mind-body or spiritual practices, which may feel more personal or less “medical” in nature.
The implication is clear: when oncologists build complementary therapy questions into their standard intake process, disclosure rates rise. When they do not, patients stay silent – not out of deception, but out of deference to the structure of the visit.
Are Cancer Patients Afraid Their Doctor Will Disapprove?
Fear of physician disapproval is the second most documented barrier to disclosure. A systematic review of 21 studies identified this fear as a primary driver of silence, particularly among patients who perceived their oncologists as exclusively focused on conventional protocols.
In this dynamic, mentioning acupuncture, meditation, or supplements can feel like challenging the oncologist’s authority or signaling distrust in conventional treatment. Patients worry about being labeled as noncompliant or irrational. Even Dr. Jun J. Mao, Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center and President of the Society for Integrative Oncology, has acknowledged this tension, noting that “skepticism is a healthy thing” and that it ultimately helps the field improve.
The irony is that the fear itself creates the danger patients are trying to avoid. When patients hide supplement use out of fear of judgment, they deny their oncology team the information needed to ensure treatment safety.
Do Patients Believe Complementary Therapies Are Irrelevant to Cancer Care?
The third documented barrier is patients’ belief that complementary therapies fall outside the scope of their oncology visit. The JAMA Oncology 2019 study found that 47.4% of patients who did not disclose believed it was simply unnecessary to do so. This reflects a compartmentalized view of health where a yoga practice or meditation routine occupies a separate domain from chemotherapy and radiation.
The systematic review of 21 studies confirmed this pattern: many patients view complementary therapies as personal wellness activities unrelated to their cancer treatment plan. This perspective, while understandable, misses the reality that even seemingly benign practices can interact with treatment protocols – and that coordinated care yields better outcomes than care delivered in silos.
What Are the Real Risks When Patients Stay Silent About Complementary Therapies?
Nondisclosure of complementary therapy use creates clinically significant risks including drug-supplement interactions, delayed recognition of side effects, and the potential for patients to substitute unproven approaches for effective treatment. These risks are greatest precisely when communication is absent, because oncologists cannot account for variables they do not know about.
Even in the category with the lowest nondisclosure rate – herbal supplements at 11.8% – the hidden use among the remaining patients represents a meaningful clinical blind spot. When a patient takes a supplement that alters liver enzyme activity or blood clotting, and the oncologist does not know, dose adjustments and safety monitoring proceed on incomplete information.
Can Herbal Supplements Interfere With Chemotherapy or Cancer Treatment?
Yes. The NCCIH states explicitly that some dietary supplements can interfere with cancer treatments by altering how drugs are metabolized, increasing toxicity, or reducing treatment efficacy. Certain herbal products affect the same liver enzyme pathways (particularly the cytochrome P450 system) that process chemotherapy drugs, creating the potential for dangerous interactions.
This is not an argument against supplements. It is an argument for coordination. When oncologists know what a patient is taking, they can advise on timing, adjust dosages, or flag specific interactions. Disclosure enables safe integration – silence creates risk. Patients exploring evidence-based habits that reduce cancer risk should always include their oncology team in the conversation.
What Happens When Complementary Therapies Replace Conventional Cancer Treatment?
When patients abandon conventional treatment entirely in favor of unproven alternatives, outcomes worsen significantly. The 2023 study in The Oncologist found that 39% of U.S. adults believe cancer can be cured by alternative practices alone – a statistic that underscores how easily the complementary-versus-alternative distinction can blur in public perception.
The NCCIH is unequivocal on this point: complementary approaches should not replace conventional cancer treatment. The evidence base supports complementary therapies as additions to standard care – enhancing quality of life, managing side effects, and in some cases improving survival – but not as standalone replacements for surgery, chemotherapy, radiation, or immunotherapy.
Frequently Asked Questions
What percentage of cancer patients hide complementary therapy use from their oncologist?
Nondisclosure rates range from 20% to 77% across published studies. A 2026 PMC review found that 61.1% of cancer patients never discussed complementary and alternative medicine with their physicians. The most common reason, cited by 57.4% of non-disclosing patients in a JAMA Oncology 2019 study of 3,118 patients, was that their oncologist simply never asked about it.
Can herbal supplements interfere with chemotherapy or other cancer treatments?
Yes, certain herbal supplements can interfere with cancer treatments by altering how chemotherapy drugs are metabolized in the body. Some herbal products affect cytochrome P450 liver enzyme pathways – the same pathways that process many cancer drugs – potentially increasing toxicity or reducing treatment effectiveness. The National Center for Complementary and Integrative Health recommends disclosing all supplements to your oncology team to ensure safe coordination.
Does exercise improve survival rates for cancer patients?
The CHALLENGE trial – a Phase 3 randomized controlled trial of 889 colon cancer patients published in the New England Journal of Medicine in 2025 – found structured exercise reduced the risk of cancer recurrence or death by 28% and the risk of death by 37%. Overall survival at 8 years was 90.3% for the exercise group compared to 83.2% for controls, over a median follow-up of 7.9 years.
How effective is acupuncture for managing cancer-related pain and side effects?
The IMPACT trial published in JAMA Network Open in 2023 found that acupuncture reduced worst pain scores by approximately 2.5 to 3 points on the Brief Pain Inventory over 26 weeks in 298 patients with advanced cancer. Acupuncture also improved fatigue, insomnia, and overall quality of life. These results are now being implemented across 35 U.S. cancer centers through the PCORI-funded IMAGINE Project.
What is the difference between complementary and alternative cancer therapies?
Complementary therapies are used alongside conventional cancer treatment – such as acupuncture for chemotherapy-induced nausea while continuing standard oncology care. Alternative therapies replace conventional treatment entirely with unproven regimens. This distinction carries serious safety implications, as a 2023 study in The Oncologist found 39% of U.S. adults incorrectly believe cancer can be cured by alternative practices alone.
How should cancer patients bring up complementary therapies with their oncologist?
Cancer patients should bring a written list of all supplements, mind-body practices, and hands-on therapies to their next oncology appointment. The best time is during a treatment planning or follow-up visit rather than a brief check-in. Frame the conversation around safety by saying something like “I want to make sure nothing I am doing interferes with my treatment” – this shifts the dynamic from confession to collaboration.
What is the IMAGINE Project and when will it be available to cancer patients?
The IMAGINE Project is a PCORI-funded initiative led by Dr. Jun J. Mao at Memorial Sloan Kettering Cancer Center that deploys evidence-based acupuncture and massage protocols across 35 U.S. cancer centers. It began implementation in 2025 and is now in its first full year of operation in spring 2026, representing the shift from researching complementary therapies to offering them as standard cancer care at scale.
Is Mainstream Medicine Finally Embracing Complementary Cancer Therapies?
Mainstream oncology is undergoing a measurable shift toward integrating evidence-based complementary therapies into standard cancer care. Two landmark developments – the CHALLENGE trial published in the New England Journal of Medicine in 2025 and the IMAGINE Project launching across 35 U.S. cancer centers – signal that the gap between patient instinct and institutional practice is narrowing rapidly in 2026.
This is not a fringe movement. The institutions driving this shift include Memorial Sloan Kettering Cancer Center, the Society for Integrative Oncology, and PCORI (the Patient-Centered Outcomes Research Institute). The evidence is being published in the field’s most prestigious journals.
What Did the CHALLENGE Trial Prove About Exercise and Cancer Survival?
The CHALLENGE trial, a Phase 3 randomized controlled trial published in the New England Journal of Medicine in 2025, provided the strongest evidence to date that structured exercise improves cancer survival. The trial enrolled 889 patients with stage III colon cancer across 55 sites, with a median follow-up of 7.9 years.
| Outcome Measure | Exercise Group | Control Group | Difference |
|---|---|---|---|
| Risk of recurrence or death | 28% lower (HR 0.72) | Reference | Significant survival benefit |
| Risk of death | 37% lower (HR 0.63) | Reference | Substantial mortality reduction |
| Overall survival at 8 years | 90.3% | 83.2% | 7.1 percentage points |
The trial was named one of NEJM’s 15 Notable Articles of 2025. Lead investigator Kerry Courneya, PhD, Professor and Canada Research Chair in Physical Activity and Cancer at the University of Alberta, stated: “Our study shows that exercise is no longer just a quality-of-life intervention for cancer patients that can be offered when and where possible. It is a treatment for colon cancer that must be made available to all patients.” For patients with colon cancer exploring holistic treatment options, these findings carry direct clinical significance.
How Are Acupuncture and Massage Being Integrated Into Cancer Centers Across the U.S.?
The IMPACT trial, published in JAMA Network Open in 2023, enrolled 298 patients with advanced cancer and found that both acupuncture and massage reduced worst pain scores by approximately 2.5 to 3 points on the Brief Pain Inventory over 26 weeks. Both modalities also improved fatigue, insomnia, and overall quality of life.
These results directly catalyzed the IMAGINE Project – a PCORI-funded initiative led by Dr. Jun Mao at Memorial Sloan Kettering that is deploying evidence-based acupuncture and massage protocols across 35 U.S. cancer centers beginning in 2025. Now in its first full year of implementation in spring 2026, the IMAGINE Project represents something unprecedented: the transition from proving that complementary therapies work to making them available as standard care at scale.
Who Is Leading the Integrative Oncology Movement?
The institutional credibility behind integrative oncology’s current momentum is substantial. Dr. Jun J. Mao, MD, MSCE, holds the Laurance S. Rockefeller Chair in Integrative Medicine and serves as Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center – widely regarded as one of the world’s foremost cancer institutions. He is also a board-certified family physician, licensed acupuncturist, and President of the Society for Integrative Oncology.
The fact that Memorial Sloan Kettering has a dedicated integrative medicine department led by a physician with these credentials signals that complementary cancer therapies have moved from the margins to the mainstream of academic oncology. As Dr. Mao has noted: “I think skepticism is a healthy thing. Just like for a lot of conventional cancer treatment, there’s always skepticism, and that helps us to improve.”
How Can Cancer Patients Start Talking to Their Oncologist About Complementary Therapies?
Cancer patients can initiate the conversation about complementary therapies by bringing a written list of everything they are using – supplements, mind-body practices, and hands-on therapies – to their next oncology appointment. Since the primary barrier to disclosure is that oncologists do not ask (57.4% of cases), patients who take the initiative bridge the gap that the system has failed to close.
The best time to raise the topic is during a treatment planning visit or a follow-up appointment when there is time for discussion rather than during a brief check-in. Frame the conversation around safety and coordination: “I want to make sure nothing I am doing interferes with my treatment.” This language shifts the dynamic from confession to collaboration.
Bring documentation where possible – product labels for supplements, descriptions of therapy programs, and any relevant research you have encountered. The NCCIH recommends that patients discuss all complementary approaches with their healthcare providers to ensure coordinated, safe care.
What Questions Should You Ask Your Oncologist About Complementary Therapies?
The following questions provide a practical starting point for patients preparing to discuss complementary therapies with their oncology team:
- Are any of the supplements I am taking likely to interact with my current treatment regimen?
- Is there an integrative oncologist on staff or one you can refer me to?
- Which complementary approaches have clinical evidence supporting their use for my cancer type?
- Should I adjust the timing of any supplements around my chemotherapy or immunotherapy sessions?
- Are there structured exercise programs designed for patients in active treatment?
- Does this cancer center offer acupuncture, massage, or mind-body programs?
- What complementary approaches would you recommend I avoid during treatment?
Printing or saving this list and bringing it to an appointment transforms a vague intention into a concrete conversation.
What Should You Do If Your Oncologist Dismisses Complementary Therapies?
If an oncologist is unreceptive to discussing complementary therapies, patients should consider seeking a second opinion from an integrative oncologist. Institutions like Memorial Sloan Kettering and the 35 cancer centers participating in the IMAGINE Project demonstrate that complementary approaches are taken seriously at the highest levels of academic oncology.
A dismissive response does not mean complementary therapies lack value – it may simply mean that particular provider’s training and clinical focus do not include integrative approaches. The Society for Integrative Oncology maintains directories of credentialed integrative oncology practitioners. Holistic cancer treatment centers like EuroMed Foundation in Arizona are designed specifically to coordinate conventional and complementary approaches under one care model, eliminating the need for patients to navigate this conversation alone.
Why Does Integrated Cancer Care Close the Communication Gap?
Integrated cancer care eliminates the nondisclosure problem by building complementary therapy coordination into the treatment model itself, making separate disclosure unnecessary. When conventional oncology and complementary therapies operate within the same care team, the systemic communication failure documented across decades of research is resolved by design rather than by relying on patient initiative.
The nondisclosure gap is not fundamentally a patient problem or a physician problem – it is a systems design problem. The conventional oncology model was built around a single treatment track. When patients add a second track of complementary therapies on their own, the two tracks run in parallel without communication. Integrated care merges them.
What Is Integrative Oncology and How Does It Differ From Conventional Cancer Care?
Integrative oncology is the evidence-based combination of conventional cancer treatments with complementary therapies under coordinated medical supervision. The Society for Integrative Oncology and the NCCIH both define it as a patient-centered approach that addresses the whole person – physical symptoms, emotional wellbeing, and quality of life – while maintaining the full rigor of conventional oncology.
In conventional cancer care, a patient might receive chemotherapy from an oncologist, take vitamin D on their own, attend a yoga class at a community studio, and see a private acupuncturist – with none of these providers communicating with each other. Integrative oncology places all of these modalities within a coordinated framework where every member of the care team has visibility into the full treatment picture.
How Does a Holistic Cancer Treatment Center Coordinate Conventional and Complementary Therapies?
A holistic cancer treatment center operates on the principle that every therapy a patient receives – whether conventional or complementary – should be part of one coordinated plan. In practice, this means shared medical records across all providers, supplement reviews built into intake protocols, direct communication between oncologists and complementary practitioners, and treatment plans that account for the timing and interactions of every modality.
At EuroMed Foundation in Arizona, this integrated model is the standard of care. Rather than asking patients to disclose their complementary therapy use after the fact, the center’s approach includes complementary modalities from the beginning of treatment planning. This eliminates the fear, uncertainty, and fragmentation that drive the nondisclosure rates documented throughout the research literature.
Frequently Asked Questions About Complementary Therapies and Cancer Care
Are Complementary Cancer Therapies Safe to Use During Chemotherapy?
Some complementary therapies are safe and evidence-supported during chemotherapy, including acupuncture, massage, and structured exercise, while certain herbal supplements can interfere with chemotherapy drugs. The NCCIH recommends always disclosing all complementary approaches to your oncology team so that safety can be ensured through coordination rather than guesswork.
Does Exercise Really Improve Cancer Survival Rates?
Yes. The CHALLENGE trial – a Phase 3 randomized controlled trial of 889 colon cancer patients published in the New England Journal of Medicine in 2025 – found that structured exercise after chemotherapy reduced the risk of recurrence or death by 28% and the risk of death by 37%. Lead investigator Kerry Courneya, PhD, stated that exercise “is a treatment for colon cancer that must be made available to all patients.”
Can Acupuncture Help With Cancer Pain and Side Effects?
The IMPACT trial (JAMA Network Open, 2023) found that acupuncture reduced worst pain scores by approximately 2.5 to 3 points on the Brief Pain Inventory and improved fatigue, insomnia, and quality of life over 26 weeks in patients with advanced cancer. These results are now being implemented across 35 U.S. cancer centers through the IMAGINE Project.
What Percentage of Cancer Patients Use Complementary Therapies Without Telling Their Doctor?
Nondisclosure rates range from 20% to 77% across published studies. The JAMA Oncology 2019 study found 29.3% nondisclosure among 3,118 cancer patients, while the most recent PMC review (2026) found that 61.1% of patients never discussed complementary and alternative medicine with their physicians. The primary reason cited was that their doctor never asked (57.4%).
Should I Tell My Oncologist About Vitamins and Supplements I Am Taking?
Yes, without exception. Vitamin D (used by 32.1% of cancer patients) and fish oil (11.6%) are among the most common supplements, and some supplements can interfere with treatment efficacy or cause adverse effects when combined with cancer therapies. Disclosing supplement use enables your oncology team to coordinate care safely – it invites collaboration, not judgment.
What Is the IMAGINE Project and Why Does It Matter for Cancer Patients?
The IMAGINE Project is a PCORI-funded initiative led by Dr. Jun J. Mao at Memorial Sloan Kettering Cancer Center, deploying evidence-based acupuncture and massage protocols across 35 U.S. cancer centers beginning in 2025. It matters because it represents the institutional shift from researching whether complementary therapies work to implementing them as standard cancer care at scale.
What Should Every Cancer Patient Know About Complementary Therapies in 2026?
In spring 2026, three truths about complementary therapies and cancer care are supported by robust evidence. First, if you are using complementary therapies, you are not alone – up to 70% of cancer patients do the same. Second, the science is catching up to patient instinct, with landmark trials in the New England Journal of Medicine and JAMA validating exercise, acupuncture, and massage as clinically meaningful interventions. Third, the communication gap between patients and oncologists is a system failure, not a personal failure – but you can bridge it today by speaking up.
You can also solve it entirely by choosing a care model where conventional and complementary therapies are coordinated from the start. EuroMed Foundation in Arizona provides exactly this kind of integrated, holistic cancer treatment – where every aspect of your care is visible to every member of your team, and no therapy happens in silence. If you or someone you love is navigating cancer treatment and wants care that honors both evidence-based medicine and the full spectrum of healing, reach out to EuroMed Foundation to learn how an integrated approach can support your journey.